Page 432 - شرور شركات الأدوية

‫ﴍور ﴍﻛﺎت اﻷدوﻳﺔ‬

(73) Outterson K. Higher First Amendment Hurdles for Public Health
Regulation. New England Journal of Medicine. 2011 Aug 18;365(7):e13.

(74) Zipkin DA, Steinman MA. Interactions Between Pharmaceuti-
cal Representatives and Doctors in Training. J Gen Intern Med. 2005
Aug;20(8):777–86.

(75) Wislar JS, Flanagin A, Fontanarosa PB, DeAngelis CD. Honorary
and ghost authorship in high impact biomedical journals: a cross sectional
survey. BMJ. 2011 Oct 25;343(oct25 1):d6128-d6128.

(76) Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman
DG, Chan A-W. Ghost Authorship in Industry-Initiated Randomised Trials.
PLoS Med. 2007 Jan 16;4(1):e19.

(77) ‘Ghost writing in the medical literature’ 111th Congress, United
States Senate Committee on Finance Sen. Charles E. Grassley, 2010.
[cited 2012 Mar 24]. Available from: http://www.grassley.senate.gov/
about/upload/Senator-Grassley-Report.pdf.

(78) Richard Horton PI 108, House of Commons—Health—Minutes
of Evidence [Internet]. [cited 2012 Mar 24]. Available from: http://
www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/
4121604.htm.

(79) Lilly ‘Ghostwrote’ Articles to Market Drug, Files Say (Update2)—
Bloomberg [Internet]. [cited 2012 Mar 24]. Available from: http://www
.bloomberg.com/apps/news?pid=newsarchive&sid=a6yFu_t9NyTY.

(80) http://www.psychiatrynorthwest.co.uk/general_adult_psychiat
ry/spr_posts/salford-haddad/index.html.

(81) Medical Press Pre-Launch Feature Outline, Zyprexa MDL 1596,
confidential subject to protection order ZY200187608. http://zyprexaliti
gationdocuments.com/percent5Cdocumentspercent5CConfidentiality-

432